Omeros Stock Price, News & Analysis (NASDAQ:OMER)

$10.00 +1.00 (+11.11 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$10.00
Today's Range$9.11 - $10.18
52-Week Range$8.66 - $27.09
Volume1.63 million shs
Average Volume1.07 million shs
Market Capitalization$533.38 million
P/E Ratio-7.75
Dividend YieldN/A
Beta3.3

About Omeros (NASDAQ:OMER)

Omeros logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorBio Therapeutic Drugs
SymbolNASDAQ:OMER
CUSIP68214310
Phone+1-206-6765000

Debt

Debt-to-Equity Ratio8.99%
Current Ratio4.77%
Quick Ratio4.74%

Price-To-Earnings

Trailing P/E Ratio-7.75193798449612
Forward P/E Ratio-10.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$41.62 million
Price / Sales11.53
Cash FlowN/A
Price / CashN/A
Book Value($0.87) per share
Price / Book-11.49

Profitability

Trailing EPS($1.29)
Net Income$-66,740,000.00
Net Margins-88.42%
Return on EquityN/A
Return on Assets-42.19%

Miscellaneous

Employees154
Outstanding Shares48,000,000

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) issued its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.18. The biopharmaceutical company earned $21.66 million during the quarter, compared to analysts' expectations of $17.82 million. The firm's revenue was up 91.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.34) earnings per share. View Omeros' Earnings History.

When will Omeros make its next earnings announcement?

Omeros is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Omeros.

Where is Omeros' stock going? Where will Omeros' stock price be in 2018?

8 brokerages have issued 1 year target prices for Omeros' shares. Their predictions range from $4.00 to $75.00. On average, they expect Omeros' share price to reach $31.57 in the next year. View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:

  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (11/15/2017)
  • 2. Maxim Group analysts commented, "Omeros announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans. These data describe up to one-year follow-up of patients treated with OMS721 in the glomerulonephropathy Phase 2 clinical trial. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin- associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system." (11/6/2017)
  • 3. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
  • 4. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)

Are investors shorting Omeros?

Omeros saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,251,440 shares, an increase of 17.3% from the January 12th total of 7,034,714 shares. Based on an average daily volume of 679,248 shares, the short-interest ratio is currently 12.1 days. Currently, 18.3% of the company's stock are short sold.

Who are some of Omeros' key competitors?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:

  • Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
  • Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 58)
  • Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary (Age 57)
  • Thomas J. Cable, Lead Independent Director (Age 77)
  • Peter A. Demopulos M.D., Director (Age 61)
  • Ray Aspiri, Independent Director (Age 78)
  • Arnold C. Hanish, Independent Director (Age 69)
  • Leroy E. Hood M.D., Ph.D., Independent Director (Age 78)

Who owns Omeros stock?

Omeros' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (11.12%), Cpwm LLC (2.26%), Capital Analysts LLC (1.23%), Geode Capital Management LLC (0.82%), Tocqueville Asset Management L.P. (0.60%) and Bank of New York Mellon Corp (0.45%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Who sold Omeros stock? Who is selling Omeros stock?

Omeros' stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Allianz Asset Management GmbH, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Raymond James & Associates, Metropolitan Life Insurance Co. NY, TIAA CREF Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold Omeros company stock in the last year include Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros.

Who bought Omeros stock? Who is buying Omeros stock?

Omeros' stock was acquired by a variety of institutional investors in the last quarter, including Capital Analysts LLC, Ingalls & Snyder LLC, First Trust Advisors LP, Deutsche Bank AG, Virtus Fund Advisers LLC, Millennium Management LLC, Wells Fargo & Company MN and Fox Run Management L.L.C.. View Insider Buying and Selling for Omeros.

How do I buy Omeros stock?

Shares of Omeros can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of Omeros stock can currently be purchased for approximately $10.00.

How big of a company is Omeros?

Omeros has a market capitalization of $533.38 million and generates $41.62 million in revenue each year. The biopharmaceutical company earns $-66,740,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Omeros employs 154 workers across the globe.

How can I contact Omeros?

Omeros' mailing address is 201 Elliott Ave W, SEATTLE, WA 98119-4240, United States. The biopharmaceutical company can be reached via phone at +1-206-6765000.


MarketBeat Community Rating for Omeros (OMER)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  422 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  633
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Omeros (NASDAQ:OMER) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.883.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $31.57$36.17$36.17$33.38
Price Target Upside: 186.75% upside110.52% upside156.87% upside57.06% upside

Omeros (NASDAQ:OMER) Consensus Price Target History

Price Target History for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/19/2018HC WainwrightSet Price TargetBuy$30.00LowView Rating Details
2/15/2018Maxim GroupSet Price TargetBuy$24.00MediumView Rating Details
2/14/2018Bank of AmericaBoost Price Target$2.44 -> $4.00LowView Rating Details
11/28/2017WedbushReiterated RatingOutperform$47.00HighView Rating Details
11/2/2017CowenDowngradeOutperform -> Market PerformN/AView Rating Details
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 -> $19.00HighView Rating Details
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00HighView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Omeros (NASDAQ:OMER) Earnings History and Estimates Chart

Earnings by Quarter for Omeros (NASDAQ:OMER)

Omeros (NASDAQ OMER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/9/2017Q3 2017($0.34)($0.16)$17.82 million$21.66 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.48)($0.20)$12.71 million$12.91 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.35)($0.37)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.38)($0.46)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.38)($0.24)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.42)($0.30)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.52)($0.33)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.40)($0.35)ViewN/AView Earnings Details
8/10/2010Q2 2010($0.34)($0.37)ViewN/AView Earnings Details
5/12/2010Q1 2010($0.33)($0.31)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.27)($0.28)ViewN/AView Earnings Details
11/19/2009Q3 2009($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Omeros (NASDAQ:OMER) Earnings Estimates

2018 EPS Consensus Estimate: ($0.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181$0.02$0.02$0.02
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Omeros (NASDAQ:OMER)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Omeros (NASDAQ OMER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 50.95%
Insider Trades by Quarter for Omeros (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Omeros (NASDAQ OMER) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2018Michael A JacobsenVPSell1,020$22.45$22,899.008,520View SEC Filing  
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.0019,500View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.002,650View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.0040,067View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.841,987,025View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.001,987,025View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.401,987,025View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.601,801,381View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00179,597View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00179,497View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00179,497View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00179,497View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00179,497View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00179,497View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.0049,467View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00138,426View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16185,182View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Omeros (NASDAQ OMER) News Headlines

Source:
DateHeadline
Omeros (OMER) PT Set at $30.00 by HC WainwrightOmeros (OMER) PT Set at $30.00 by HC Wainwright
www.americanbankingnews.com - February 20 at 8:58 PM
Omeros Co. (OMER) Given Average Recommendation of "Buy" by AnalystsOmeros Co. (OMER) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 20 at 3:58 PM
Omeros (OMER) PT Set at $24.00 by Maxim GroupOmeros (OMER) PT Set at $24.00 by Maxim Group
www.americanbankingnews.com - February 15 at 5:40 PM
Comparing Retrophin (RTRX) and Omeros (OMER)Comparing Retrophin (RTRX) and Omeros (OMER)
www.americanbankingnews.com - February 15 at 5:10 PM
Omeros (OMER) Reports Significant Improvement in OS Data in OMS721-Treated Patients with HCT-TMAOmeros (OMER) Reports Significant Improvement in OS Data in OMS721-Treated Patients with HCT-TMA
www.streetinsider.com - February 15 at 4:55 PM
Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic MicroangiopathyOmeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
finance.yahoo.com - February 15 at 4:55 PM
Omeros’ (OMER) Robust Sales Growth Make it a Buy at recent price of $11.24Omeros’ (OMER) Robust Sales Growth Make it a Buy at recent price of $11.24
investorplace.com - February 15 at 1:12 PM
This Mornings Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec MedicalThis Morning's Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec Medical
www.prnewswire.com - February 15 at 6:54 AM
Why Biogen, Groupon, and Omeros Slumped TodayWhy Biogen, Groupon, and Omeros Slumped Today
finance.yahoo.com - February 15 at 6:49 AM
The Report that Sent Omeros Corporation (OMER) Shares TumblingThe Report that Sent Omeros Corporation (OMER) Shares Tumbling
finance.yahoo.com - February 15 at 6:49 AM
Omeros (OMER) Cut to "Sell" at ValuEngineOmeros (OMER) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - February 14 at 11:12 PM
Omeros (OMER) PT Raised to $4.00Omeros (OMER) PT Raised to $4.00
www.americanbankingnews.com - February 14 at 4:54 PM
Short Seller Who Predicted Plunge in Flotek Has a New TargetShort Seller Who Predicted Plunge in Flotek Has a New Target
finance.yahoo.com - February 14 at 3:28 PM
Here's Why Omeros Corporation Is Getting Beaten Down on WednesdayHere's Why Omeros Corporation Is Getting Beaten Down on Wednesday
finance.yahoo.com - February 14 at 3:28 PM
Heres Why Omeros Corporation Is Getting Beaten Down on WednesdayHere's Why Omeros Corporation Is Getting Beaten Down on Wednesday
www.fool.com - February 14 at 1:31 PM
$23.45 Million in Sales Expected for Omeros Co. (OMER) This Quarter$23.45 Million in Sales Expected for Omeros Co. (OMER) This Quarter
www.americanbankingnews.com - February 11 at 4:30 AM
Omeros Co. (OMER) Sees Significant Growth in Short InterestOmeros Co. (OMER) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 9 at 4:58 PM
Omeros (OMER) Upgraded to "Hold" by ValuEngineOmeros (OMER) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - February 4 at 7:10 PM
Omeros Co. (OMER) Receives Average Recommendation of "Buy" from AnalystsOmeros Co. (OMER) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 26 at 3:36 PM
Zacks: Analysts Expect Omeros Co. (OMER) Will Post Earnings of -$0.16 Per ShareZacks: Analysts Expect Omeros Co. (OMER) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - January 23 at 9:26 PM
Omeros (OMER) Given a $30.00 Price Target by HC Wainwright AnalystsOmeros (OMER) Given a $30.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - January 23 at 8:08 AM
Omeros (OMER) Given a $24.00 Price Target at Maxim GroupOmeros (OMER) Given a $24.00 Price Target at Maxim Group
www.americanbankingnews.com - January 22 at 7:16 PM
Omeros Scores Relative Strength Rating Upgrade; Hits Key ThresholdOmeros Scores Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - January 11 at 10:47 AM
This Is Why Omeros Jumped 95.8% in 2017This Is Why Omeros Jumped 95.8% in 2017
finance.yahoo.com - January 10 at 4:33 PM
Wedbush Equities Analysts Reduce Earnings Estimates for Omeros Co. (OMER)Wedbush Equities Analysts Reduce Earnings Estimates for Omeros Co. (OMER)
www.americanbankingnews.com - January 8 at 6:40 PM
 Analysts Anticipate Omeros Co. (OMER) Will Post Earnings of -$0.16 Per Share Analysts Anticipate Omeros Co. (OMER) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - January 6 at 7:14 PM
Insider Selling: Omeros Co. (OMER) VP Sells 1,020 Shares of StockInsider Selling: Omeros Co. (OMER) VP Sells 1,020 Shares of Stock
www.americanbankingnews.com - January 5 at 9:12 PM
Equities Analysts Set Expectations for Omeros Co.s FY2022 Earnings (OMER)Equities Analysts Set Expectations for Omeros Co.'s FY2022 Earnings (OMER)
www.americanbankingnews.com - January 5 at 8:24 PM
Today’s Research Reports on Trending Tickers: HTG Molecular Diagnostics and Omeros CorporationToday’s Research Reports on Trending Tickers: HTG Molecular Diagnostics and Omeros Corporation
finance.yahoo.com - January 5 at 10:33 AM
At $20.155, Is Omeros Corporation (NASDAQ:OMER) A Buy?At $20.155, Is Omeros Corporation (NASDAQ:OMER) A Buy?
finance.yahoo.com - January 4 at 10:18 AM
Omeros (OMER) Given "Buy" Rating at HC WainwrightOmeros (OMER) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - January 4 at 8:00 AM
Omeros Corporation (OMER) Provides Regulatory Update on OMS721; Shares Soar 8%Omeros Corporation (OMER) Provides Regulatory Update on OMS721; Shares Soar 8%
finance.yahoo.com - January 3 at 4:37 PM
Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA NephropathyOmeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
finance.yahoo.com - January 3 at 9:37 AM
Omeros Co. (OMER) Given Consensus Rating of "Buy" by AnalystsOmeros Co. (OMER) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 1 at 3:42 PM
ETFs with exposure to Omeros Corp. : December 26, 2017ETFs with exposure to Omeros Corp. : December 26, 2017
finance.yahoo.com - December 26 at 3:16 PM
Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:02 PM
Omeros Co. (OMER) Expected to Post Quarterly Sales of $23.45 MillionOmeros Co. (OMER) Expected to Post Quarterly Sales of $23.45 Million
www.americanbankingnews.com - December 23 at 8:30 AM
 Analysts Expect Omeros Co. (OMER) Will Post Earnings of -$0.16 Per Share Analysts Expect Omeros Co. (OMER) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - December 21 at 11:24 AM
Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - December 21 at 10:21 AM
Omeros OMIDRIA Eye Drop OKed For Pediatric UseOmeros' OMIDRIA Eye Drop OK'ed For Pediatric Use
finance.yahoo.com - December 12 at 4:50 PM
Here's Why Omeros Corporation Is Gaining More Ground TodayHere's Why Omeros Corporation Is Gaining More Ground Today
finance.yahoo.com - December 12 at 4:50 PM
Heres Why Omeros Corporation Is Gaining More Ground TodayHere's Why Omeros Corporation Is Gaining More Ground Today
www.fool.com - December 12 at 1:43 PM
Maxim Group Analysts Give Omeros (OMER) a $24.00 Price TargetMaxim Group Analysts Give Omeros (OMER) a $24.00 Price Target
www.americanbankingnews.com - December 12 at 11:28 AM
Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric PatientsOmeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients
finance.yahoo.com - December 12 at 10:50 AM
Omeros Corporation (OMER) Given Average Recommendation of "Buy" by BrokeragesOmeros Corporation (OMER) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 7 at 4:01 PM
How Pharma And Life Sciences M&A Activity Shows Omeros Corporation Is Extremely Undervalued - Seeking AlphaHow Pharma And Life Sciences M&A Activity Shows Omeros Corporation Is Extremely Undervalued - Seeking Alpha
seekingalpha.com - December 6 at 10:40 AM
Why The Volatility In Omeros Corporation? - Seeking AlphaWhy The Volatility In Omeros Corporation? - Seeking Alpha
seekingalpha.com - December 5 at 12:04 PM
Today’s Research Reports on Stocks to Watch: Omeros Corporation and Ohr PharmaceuticalToday’s Research Reports on Stocks to Watch: Omeros Corporation and Ohr Pharmaceutical
finance.yahoo.com - December 4 at 10:21 AM
Omeros Earns Relative Strength Rating UpgradeOmeros Earns Relative Strength Rating Upgrade
finance.yahoo.com - December 1 at 5:39 PM
FY2017 Earnings Forecast for Omeros Corporation (OMER) Issued By WedbushFY2017 Earnings Forecast for Omeros Corporation (OMER) Issued By Wedbush
www.americanbankingnews.com - November 30 at 6:56 AM

SEC Filings

Omeros (NASDAQ:OMER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Omeros (NASDAQ:OMER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Omeros (NASDAQ OMER) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.